Biggest News Aggregation in the World
📰 Simcere Pharmaceutical News

Page 2 - Simcere Pharmaceutical News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Simcere Pharmaceutical. Real-time updates on events, politics, business and more.

Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue

/PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) announced its financial results for the first half of 2022. As of June 30, Simcere recorded...
United States Hong Kong Prnewswire Simcere Pharmaceutical Group Hong Kong Stock Exchange Simcere Pharmaceutical Group Simcere Pharmaceutical

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Kazia Therapeutics Ltd lands trifecta of licensing deals in March quarter, leaving it "a vastly stronger and more substantial business"

Kazia Therapeutics lands trifecta of licensing deals in March quarter, leaving it "a vastly stronger and more substantial business" During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million end-March.  These transactions leave Kazia a vastly stronger and more substantial business, with a diversified pipeline of world-class oncology assets. Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FR...
Hong Kong Simcere Pharmaceutical Simcere Pharmaceutical Group Ltd Oasmia Pharmaceutical Greater China ஹாங் காங்

Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801

Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 DGAP-News: Evotec SE / Key word(s): Miscellaneous 19.04.2021 / 08:31 The issuer is solely responsible for the content of this announcement. EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ASSET EVT801 KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURI...
New South Wales Volker Braun Gabriele Hansen Kazia Therapeutics Limited Simcere Pharmaceutical Company Boehringer Ingelheim

Evotec AG: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801

Evotec AG: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ("CMC") EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES HAMBURG, GERMANY / ACCESSWIRE / April 19, 2021 / Evotec SE ...
New South Wales Volker Braun Gabriele Hansen Kazia Therapeutics Limited Simcere Pharmaceutical Company Boehringer Ingelheim

PRESS RELEASE: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801

Message : Required fields DGAP-News: Evotec SE / Key word(s): Miscellaneous Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 2021-04-19 / 08:31 The issuer is solely responsible for the content of this announcement. =---------------------------------------------------------------------------------------------------------------------- . EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ...
New South Wales Volker Braun Manfred Eigen Gabriele Hansen English Company Kazia Therapeutics Limited

Kazia Therapeutics presents PK data for paxalisib at AACR meeting

Kazia Therapeutics Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian  oncology-focused drug development company, is pleased to share new data from its  ongoing phase II study of paxalisib in glioblastoma, the most common and most aggressive form of primary brain cancer. The data is the subject of a poster presentation at the American Association of Cancer  Research (AACR) Annual Meeting, which is being held virtually from 10-15 April 2021, and  from 17-21 May 2021. Key...
United States New South Wales James Garner Kazia Therapeutics Limited Simcere Pharmaceutical Company American Association Of Cancer

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science